Current Report Filing (8-k)
January 09 2017 - 5:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): December 29, 2016
Anika Therapeutics, Inc.
|
(Exact name of registrant as specified in its charter)
|
Massachusetts
|
000-21326
|
04-3145961
|
(State or other jurisdiction of
incorporation or
organization)
|
Commission file number
|
(I.R.S. Employer
Identification No.)
|
32 Wiggins Avenue, Bedford, MA 01730
|
(Address of principal executive offices) (Zip code)
|
Registrant's telephone number, including area code
: 781-457-9000
(Former name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under
any of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 1.02. Termination of a Material Definitive Agreement.
On December 29, 2016, Anika Therapeutics S.r.l. (formerly Fidia Advanced
Biopolymers S.r.l.) (“Anika S.r.l”), the wholly-owned Italian subsidiary
of Anika Therapeutics, Inc. (together with Anika S.r.l., the “Company”)
notified Fidia Farmaceutici S.p.A. (“Fidia”) of its intention to
terminate the lease agreement between Anika S.r.l. and Fidia, originally
executed on December 30, 2009, for the facility that serves as the
current headquarters for Anika S.r.l. (the “Lease”) as of March 31,
2017. On October 5, 2015, Anika S.r.l. entered into a build-to-suit
lease agreement with Consorzio Zona Industriale E Porto Fluviale di
Padova pursuant to which Anika S.r.l. will lease a new headquarters
space in Padova, Italy, into which Anika S.r.l. will move the entirety
of its operations upon its certification for occupancy and which will
serve as the Company’s European headquarters moving forward. No
termination or other fees are payable in connection with the termination
of the Lease. In addition to the Lease, Anika S.r.l. has previously
entered into a Tolling Agreement with Fidia, executed on December 30,
2009, whereby Fidia manufactures certain product intermediates and
finished products for Anika S.r.l.
A summary of the material terms of the Lease was included in the
Company’s Current Report on Form 8-K filed on January 6, 2010, which is
qualified in its entirety by reference to the full text of the Lease
(filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed
on January 6, 2010 and incorporated herein by reference) and the full
text of Amendment No. 1 to Lease Agreement, Amendment No. 2 to Lease
Agreement, Translation of Amendment No. 3 to Lease Agreement, and
Translation of Amendment No. 4 to Lease Agreement (filed as Exhibit
10.2, Exhibit 10.3, Exhibit 10.4, and Exhibit 10.5 to the Company’s
Quarterly Report on Form 10-Q filed on May 3, 2016, respectively, and
incorporated herein by reference).
[Remainder of page left blank intentionally]
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be filed on its behalf by the
undersigned hereunto duly authorized.
|
Anika Therapeutics, Inc.
|
|
|
|
|
Dated: January 9, 2017
|
By:
|
/s/ Sylvia Cheung
|
|
|
|
Sylvia Cheung
|
|
|
|
Chief Financial Officer
|
|
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Sep 2023 to Sep 2024